Clearmind Medicine Inc. (NASDAQ: CMND) announced the completion of treatment for all 24 participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for alcohol use disorder.

Participants across cohorts 1 through 4 completed treatment according to the study protocol. The trial is being conducted under FDA oversight at multiple sites in the United States and Israel, including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

The company said it is currently reviewing the dataset and intends to initiate the next stage of the clinical program in alcohol use disorder patients, assuming results remain favorable.

"We are pleased to have successfully completed treatment for all participants in Part A of the study, fully aligned with the clinical protocol," said Adi Zuloff-Shani, PhD, CEO of Clearmind. "With data review now underway, we are eager to progress to the next phase of development and continue advancing CMND-100 as a promising therapeutic candidate for Alcohol Use Disorder."

Clearmind is a clinical-stage biotechnology company focused on developing non-hallucinogenic, neuroplastogen-derived treatments. The company's intellectual portfolio includes 19 patent families and 32 granted patents.